17,261 trials
HIV · HIV Pre-exposure Prophylaxis
Primary: Number of Participants With ≥1 Adverse Event (AE) — 62; 69; 66; 31 Participants
Hidradenitis Suppurativa
Primary: Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 12 — -2.93; -5.94 AN count — p=>0.999
Contraception
Primary: Number of Subjects With Poor Cervical Mucus Scores During Treatment Period — 3; 11 Participants
Functional Constipation
Primary: Change From Baseline in Overall Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) During the Study Intervention Period — 3.181; 2.503; 0.246; 3.371 SBMs/Week
NAFLD · Nonalcoholic Fatty Liver · NASH - Nonalcoholic Steatohepatitis
Primary: Intrahepatic Lipid Content (IHL, Percent Liver Fat) — 3.9 absolute change in percentage liver fat — p=0.4
Kaposiform Hemangioendotheliomas · Tufted Angioma · Capillary Venous Lymphatic Malformation
Primary: Overall Response by Radiologic Evaluation, Quality of Life Assessment, and Functional Impairment Score — 47; 7; 3 Participants
Neoplasms by Site
Primary: Number of Participants With Adverse Events, Deaths and Clinically Relevant Laboratory Abnormalities — 5; 4; 4; 12 Participants
Non-Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) as Assessed Per RECIST v1.1 — 0; 11 Participants
NASH - Nonalcoholic Steatohepatitis
Primary: Main Study: Number of Participants With Histological Resolution of Nonalcoholic Steatohepatitis (NASH) Without Worsening of Fibrosis — 5; 12; 11; 1 Participants…
Non-cystic Fibrosis Bronchiectasis · Pseudomonas Aeruginosa · Lung Infection
Primary: P. Aeruginosa Recovery in Sputum Following Multiple Doses of AP-PA02 Administered by Inhalation — -0.5; -0.1; -0.4; 1.0 colony forming units log10
Non-Small Cell Lung Cancer
Primary: Overall Response Rate — 0.0; 0.0 percentage of participants
Glaucoma · Ocular Hypertension
Primary: Mean Diurnal IOP — -5.07; -4.73; -4.6 mmHg — p=0.376
Heart Failure With Reduced Ejection Fraction · HIV Infections
Primary: Measured Adherence to GDMT by Pill Count — 74.6; 83.3 adherence ratio expressed in %
Irritable Bowel Syndrome With Constipation
Primary: Change From Baseline in Weekly Spontaneous Bowel Movement (SBM) Frequency Over the 4 Week Treatment Period Compared to Placebo and Across Treatment Groups — 0.6; 0.8…
Acute Ischemic Stroke
Primary: The Percentage of Subject Have Symptomatic Intracranial Hemorrhage (sICH) of a Single Dose LT3001 Drug Product in Subjects With AIS. — 0; 0 Participants